A total of 566 patients with vaficeal bleeding caused by cirrhosis of the liver, noncirrhotic portal fibrosis (NCPF) 
INTRODUCTION
Since 1981, we have been injecting esophageal varices during active variceal bleeding and for long-term management after variceal bleeding (1) (2) (3) (4) . In India, besides cirrhosis of the liver, two other diseases, noncirrhotic portal fibrosis (NCPF), and extrahepatic portal venous obstruction (EHO) are also responsible for portal hypertension (5) .
Between 1981 and 1993, we treated 566 patients with portal hypertension, who had bleeding from esophageal varices. The varices were caused by cirrhosis of the liver, NCPF, and EHO. These are few studies on the long-term results of the use of endoscopic sclerotherapy (EST) for the management of patients who had bled from esophagastic varices as in the present study. The efficacy of this mode of treatment is retrospectively reviewed. This study also compares the results among the three groups of patients. This is one ofthe largest groups ofpatients reported with a long and complete follow-up.
METHODS
with NCPF and 117 with EHO ( Table 1 ). The etiology of cirrhosis was alcohol-related in 119, posthepatic in 91, and cryptogenic in 132 patients. Informed consent was obtained from all patients. All of them were seen with endoscopically documented variceal hemorrhage requiring blood transfusion in the recent past (< 30 days).
In each patient endoscopy confirmed grade 3 or 4 esophageal varices (6) . All (1) . The injections were repeated every 3 weeks until July 1991. Subsequently, the varices were injected weekly. After eradication, endoscopic examination was repeated every 3 to 6 months to observe 
Rebleeding Parameters
Patients Rebleeding The numbers ofpatients whose varices rebled between the first session of EST and eradication in the different etiological subgroups and stratified for Child's scores are given in Table 3 . Significantly more patients with cirrhosis had rebleeding (27.7%) compared with those with EHO (P < 0.0001). The number of patients with NCPF who had rebleeding (24.3%) was significantly more (P < 0.05) than those with EHO (11.1%). There was no difference in the rebleeding rates between patients with cirrhosis and NCPF (P > 0.1). 
Survival
An analysis ofthe survival by the Kaplan-Meier technique showed that the probability of survival at 10 years was 50, 80, and 88% in patients with cirrhosis, NCPF, and EHO, respectively (Fig. 3) . Patients with NCPF and EHO survived longer than patients with cirrhosis (P < 0.01). There was no statistical differences between patients with NCPF and EHO (P > 0.05). The probability ofsurvival at 10 years was 88% for Child's A, 42% Child's B, and 0% for Child's C class patients (Fig. 4) . Patients belonging to Child's A status irrespective ofetiology had significantly (P < 0.001) longer survival than those ofChild's B or C class. Similarly patients of Child's B status survived longer than those of Child's C status (P < 0.01).
Complications
Complications such as retrosternal pain, fever of > 100F, deep ulcers, dysphagia, stricture, mediastinitis, pneumonia, and pleural effusions were observed in 15% of our patients after EST. The Child's status and the etiology of portal hypertension did not influence the incidence of complications significantly. Mucosal slough or local superficia ulcers were excluded from the list of complications as they were usually of little significance in the overall management of the patients. 
DISCUSSION
Repeated sclerotherapy has been found to be a safe and effective mode oftreatment for the long-term management of esophageal variceal bleeding irrespective of the etiology ofportal hypertension. This is supported by controlled and prospective trials (1-3,8,9 ). The place of long-term 13-blockade remains controversial (10) . Surgical procedures have significant morbidity and mortality. One of the major disadvantages of repeated EST was rebleeding episodes before eradication of varices. These occurred more often in patients of Child's C status than in those of Child's B class and more in Child's B status than Child's A status patients in the present study. Similarly, patients with better hepatic function had a significantly longer BFP. In terms of etiology, results of rebleeding parameters favored patients with EHO more than those with NCPF and cirrhosis of the liver. This was supported by the observation that there was no significant difference between different etiologic categories within each Child's class. Similar observations have been made by Sakai et al. (11) reported better results in patients with schistosomiasis than in those with cirrhosis.
It was observed that rebleeding episodes were insignificant once the varices are eradicated. This was achieved in 80% of patients with cirrhosis, 87% of patients with NCPF, and 90% of patients with EHO. The mean number of sclerotherapy sessions required for eradication were comparable in the three groups. Eradication rate was better achieved in Child's A class patients than in Child's B and Child's C class patients (P < 0.05). It was difficult to eradicate varices in the remaining patients, and in many of varices continue to bleed intermittently. These should be considered as sclerotherapy failures. Such patients should probably be subjected to an alternate procedure such as surgery or endoscopic band ligation. Terblanche et al. (9) also reported that 10% of their patients failed to respond to sclerotherapy. The recurrence of varices was observed in 21% of patients after a mean period of 38.9 + 22.6 months irrespective of etiology or Child's status. The lower incidence of recurrence in our series was possibly due to total eradication of varices at the begining of treatment and a regular follow-up of patients at an interval of 3 to 6 months. Thus, prevention of recurrent bleeding was dependent upon the successful eradication of varices, and regular surveillance is necessary to ensure eradication.
It is not yet clear whether repeated sclerotherapy improves survival. Meta analysis of the data from controlled trials did, however, show a survival advantage for sclerotherapy (12 (9, 11) and has also been emphasized by us in the past (1) .
Usually, complications related to the procedure were minor except for esophageal stricture formation, mediastinitis, pleural effusion, and pneumonia. Superficial ulcers and mucosal slough were oflittle significance as they were only encountered during repeated endoscopy. It is suggested that this leads to better eradication of varices and control of recurrent bleeding episodes (13, 14) . Complications also vary with the type ofsclerosant (15, 16) used as well as the quantity, concentration, and frequency of injections (17) .
Thus, the present study confirms that repeated endoscopic sclerotherapy prevents rebleeding by eradication of varices. The results were influenced primarily by the functional hepatic status and indirectly by the etiology of portal hypertension. Eradication is most successful in patients with EHO, followed by NCPF and cirrhosis of the liver. It is difficult to comment whether eradication of varices increases the survival. However, at least patients with EHO and NCPF have an excellent survival rate. On the basis of our observations, repeated endoscopic sclerotherapy is the procedure of choice for the long-term management of esophageal varices at our center, irrespective of the etiology of portal hypertension and their functional status. We are injecting varices every week with 1% polidocanol until they are eradicated. In case of failure of sclerotherapy, we resort to either endoscopic band ligation or surgery. Once the vadces are eradicated, endoscopy is performed at an interval of 3 to 6 months to detect early recurrence of varices. Recurrent vadces should be treated similarly.
